Integrated analysis of the overall exosome levels allowed the quantification of CD9 (+) and CD81(+) from human plasma in ovarian cancer (nano-IMEX) [100] and NSCLC [109], and CD63(+) in pancreatic cancer (ExoChip) [99]. Here, CD63 is linked to ovarian cancer.